A complementary downstream mechanism involves immunomodulatory effects, consisting of inhibition of proinflammatory cytokine release, such as TNF-α and IL-6, via 5-HT2A agonism, potentially attenuating the inflammatory component of MDD. Here, TNF is linked to major depressive disorder.